A Centralized Program with Stepped Support Increases Adherence to Colorectal Cancer Screening Over 9 Years: a Randomized Trial

Beverly B Green, Melissa L Anderson, Andrea J Cook, Jessica Chubak, Sharon Fuller, Richard T Meenan, Sally W Vernon, Beverly B Green, Melissa L Anderson, Andrea J Cook, Jessica Chubak, Sharon Fuller, Richard T Meenan, Sally W Vernon

Abstract

Background: Screening over many years is required to optimize colorectal cancer (CRC) outcomes.

Objective: To evaluate the effect of a CRC screening intervention on adherence to CRC screening over 9 years.

Design: Randomized trial.

Setting: Integrated health care system in Washington state.

Participants: Between August 2008 and November 2009, 4653 adults in a Washington state integrated health care system aged 50-74 due for CRC screening were randomized to usual care (UC; N =1163) or UC plus study interventions (interventions: N = 3490).

Interventions: Years 1 and 2: (arm 1) UC or this plus study interventions; (arm 2) mailed fecal tests or information on scheduling colonoscopy; (arm 3) mailings plus brief telephone assistance; or (arm 4) mailings and assistance plus nurse navigation. In year 3, stepped-intensity participants (arms 2, 3, and 4 combined) still eligible for screening were randomized to either stopped or continued interventions in years 3 and 5-9.

Main measures: Time in adherence to CRC testing over 9 years (covered time, primary outcome), and percent with no CRC testing in participants assigned to any intervention compared to UC only. Poisson regression models estimated incidence rate ratios for covered time, adjusting for patient characteristics and accounting for variable follow-up time.

Key results: Compared to UC, intervention participants had 21% more covered time over 9 years (57.5% vs. 69.1%; adjusted incidence rate ratio 1.21, 95% confidence interval 1.16-1.25, P<0.001). Fecal testing accounted for almost all additional covered time among intervention patients. Compared to UC, intervention participants were also more likely to have completed at least one CRC screening test over 9 years or until censorship (88.6% vs. 80.6%, P<0.001).

Conclusions: An outreach program that included mailed fecal tests and phone follow-up led to increased adherence to CRC testing and fewer age-eligible individuals without any CRC testing over 9 years.

Trial registration: Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up (SOS), NCT00697047, clinicaltrials.gov/ct2/show/NCT00697047.

Keywords: colorectal cancer; health care system; mailed fecal tests; randomized trial; screening.

© 2021. Society of General Internal Medicine.

Figures

Figure 1
Figure 1
Systems of support to increase colorectal cancer screening and follow-up flow diagram for years 1 to 9. *Individuals with a prior colonoscopy or who had a flexible sigmoidoscopy with an adenoma removed or a positive fecal test were not eligible for year 3 randomization. †Ineligibility condition; detected after randomization (e.g., dementia). ‡Other; randomized in error (i.e., colonoscopy within 9 years of initial randomization). §Randomization to stopped or continued in year 3 occurred on the date the participant was due for their third round of annual screening. lIntervention group participants did not receive study interventions in year 4. CRC, colorectal cancer; y, year.
Figure 2
Figure 2
Cumulative percent covered time by colorectal cancer test type in the usual care and intervention arms. In this figure, the cumulative percent covered time for a given year is defined as the number of days of covered time from baseline through the end of that year, divided by the total follow-up time for that person, from baseline through the end of that year or censor date.

References

    1. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164.
    1. American Cancer Society. Cancer facts & figures 2021. 2021; . Accessed April 14, 2021.
    1. Freedman JD, Mitchell CK. A simple strategy to improve patient adherence to outpatient fecal occult blood testing. J Gen Intern Med. 1994;9(8):462–464.
    1. Church TR, Yeazel MW, Jones RM, et al. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening. J Natl Cancer Inst. 2004;96(10):770–780.
    1. Coronado GD, Golovaty I, Longton G, Levy L, Jimenez R. Effectiveness of a clinic-based colorectal cancer screening promotion program for underserved Hispanics. Cancer. 2011;117(8):1745–1754.
    1. Green BB, Wang CY, Anderson ML, et al. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med. 2013;158(5 Pt 1):301–311.
    1. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med. 2013;173(18):1725–1732.
    1. Baker DW, Brown T, Buchanan DR, et al. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1235–1241.
    1. Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(12):1645–1658.
    1. Jager M, Demb J, Asghar A, et al. Mailed outreach is superior to usual care alone for colorectal cancer screening in the USA: A systematic review and meta-analysis. Dig Dis Sci. 2019;64(9):2489–2496.
    1. Singal AG, Gupta S, Skinner CS, et al. Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion. JAMA. 2017;318(9):806–815.
    1. Liang PS, Wheat CL, Abhat A, et al. Adherence to competing strategies for colorectal cancer screening over 3 years. Am J Gastroenterol. 2016;111(1):105–114.
    1. Murphy CC, Sen A, Watson B, Gupta S, Mayo H, Singal AG. A systematic review of repeat fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2020;29(2):278–287.
    1. Kapidzic A, Grobbee EJ, Hol L, et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol. 2014;109(8):1257–1264.
    1. Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011;33(1):101–110.
    1. Steele RJ, McClements PL, Libby G, Carey FA, Fraser CG. Patterns of update in a biennial faecal occult blood test screening programme for colorectal cancer. Colorectal Dis. 2014;16(1):28–32.
    1. van der Vlugt M, Grobbee EJ, Bossuyt PM, et al. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. Br J Cancer. 2017;116(1):44–49.
    1. Murphy CC, Sigel BM, Yang E, et al. Adherence to colorectal cancer screening measured as the proportion of time covered. Gastrointest Endosc. 2018;88(2):323–331. e322.
    1. Gellad ZF, Stechuchak KM, Fisher DA, et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol. 2011;106(6):1125–1134.
    1. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164(7):456–463.
    1. Systems of Support (SOS) to increase colon cancer screening and follow-up. 2008; . Accessed April 14, 2021.
    1. Green BB, Wang CY, Horner K, et al. Systems of support to increase colorectal cancer screening and follow-up rates (SOS): design, challenges, and baseline characteristics of trial participants. Contemp Clin Trials. 2010;31(6):589–603.
    1. Green BB, Bogart A, Chubak J, et al. Nonparticipation in a population-based trial to increase colorectal cancer screening. Am J Prev Med. 2012;42(4):390–397.
    1. Green BB, Anderson ML, Chubak J, et al. Colorectal cancer screening rates increased after exposure to the Patient-Centered Medical Home (PCMH) J Am Board Fam Med. 2016;29(2):191–200.
    1. Meenan RT, Anderson ML, Chubak J, et al. An economic evaluation of colorectal cancer screening in primary care practice. Am J Prev Med. 2015;48(6):714–721.
    1. Green BB, Anderson ML, Chubak J, Fuller S, Meenan RT, Vernon SW. Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial. Cancer. 2016;122(2):312–321.
    1. Green BB, Anderson ML, Cook AJ, et al. A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial. Cancer. 2017;123(22):4472–4480.
    1. Green BB, BlueSpruce J, Tuzzio L, Vernon SW, Aubree Shay L, Catz SL. Reasons for never and intermittent completion of colorectal cancer screening after receiving multiple rounds of mailed fecal tests. BMC Public Health. 2017;17(1):531.
    1. Murphy CC, Halm EA, Skinner CS, Balasubramanian BA, Singal AG. Challenges and approaches to measuring repeat fecal immunochemical test for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2020;29(8):1557–1563.
    1. Chubak J, Anderson ML, Cook AJ, Murphy CC, Jackson ML, Green BB. Methodologic considerations in calculating and analyzing proportion of time covered as a measure of longitudinal cancer screening adherence. Cancer Epidemiol Biomarkers Prev. 2020;29(8):1549–1556.
    1. National Cancer Institute. SEER Registries. . Accessed April 14, 2021.
    1. Mehta SJ, Jensen CD, Quinn VP, et al. Race/ethnicity and adoption of a population health management approach to colorectal cancer screening in a community-based healthcare system. J Gen Intern Med. 2016;31(11):1323–1330.
    1. Green BB, Meenan RT. Colorectal cancer screening: The costs and benefits of getting to 80% in every community. Cancer. 2020;126(18):4110–4113.
    1. Coronado GD, Petrik AF, Vollmer WM, et al. Effectiveness of a mailed colorectal cancer screening outreach program in community health clinics: The STOP CRC Cluster Randomized Clinical Trial. JAMA Intern Med. 2018;178(9):1174–1181.
    1. Coronado GD, Green BB, West II, et al. Direct-to-member mailed colorectal cancer screening outreach for Medicaid and Medicare enrollees: Implementation and effectiveness outcomes from the BeneFIT study. Cancer. 2020;126(3):540–548.
    1. Petrik AF, Green B, Schneider J, et al. Factors influencing implementation of a colorectal cancer screening improvement program in community health centers: an applied use of configurational comparative methods. J Gen Intern Med. 2020;35(Suppl 2):815–822.
    1. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106–1114.
    1. Kronborg O, Jørgensen O, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol. 2004;39(9):846–851.
    1. Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology. 2018;155(5):1383–1391.
    1. Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121(18):3221–3229.
    1. Hamza S, Cottet V, Touillon N, et al. Long-term effect of faecal occult blood screening on incidence and mortality from colorectal cancer. Dig Liver Dis. 2014;46(12):1121–1125.
    1. Gini A, Jansen EE, Zielonke N, et al. Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. Eur J Cancer. 2020;127:224–235.
    1. Gawron AJ, Kaltenbach T, Dominitz JA. The impact of the coronavirus disease-19 pandemic on access to endoscopy procedures in the VA healthcare system. Gastroenterology. 2020;159(4):1216–1220.
    1. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023–1034.
    1. Aguiar S, Riechelmann RP, de Mello CAL, et al. Impact of COVID-19 on colorectal cancer presentation. Br J Surg. 2021;108(2):e81–e82.
    1. Rutter MD, Brookes M, Lee TJ, Rogers P, Sharp L. Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis. Gut. 2021;70(3):537–543.
    1. Nodora JN, Gupta S, Howard N, et al. The COVID-19 pandemic: Identifying adaptive solutions for colorectal cancer screening in underserved communities. J Natl Cancer Inst. 2020.
    1. Chubak J, Hubbard R. Defining and measuring adherence to cancer screening. J Med Screen. 2016;23(4):179–185.

Source: PubMed

3
Subscribe